Gonadorelin vs PT-141
Both Gonadorelin and PT-141 are used for sexual-health. Here's how their evidence, dosing, and regulatory status actually compare.
Gonadorelin
Evidence AGonadorelin (GnRH)
Synthetic GnRH used clinically to stimulate LH/FSH release. In testosterone replacement therapy, used pulsatile to preserve testicular size and fertility instead of hCG.
View full Gonadorelin profile →PT-141
Evidence ABremelanotide (Vyleesi)
A melanocortin receptor agonist that works directly on the nervous system to increase sexual desire. The only FDA-approved peptide for sexual dysfunction that acts on the brain rather than vascular system.
View full PT-141 profile →Side-by-Side
| Attribute | Gonadorelin | PT-141 |
|---|---|---|
| Evidence Grade | A | A |
| FDA Status | FDA-approved (Factrel) historically for diagnostic GnRH stimulation; off-label use in TRT to preserve testicular function | FDA-approved for hypoactive sexual desire disorder (HSDD) in women |
| Typical Dose | 100–500 mcg every 1–3 days (subcutaneous, pulsatile) | 1.75 mg subcutaneous, 45 min before activity |
| Clinics Indexed | 156 | 210 |
| Categories | sexual-health, fertility | sexual-health |
Key reported benefits — Gonadorelin
- ✓LH/FSH stimulation
- ✓Testicular preservation on TRT
- ✓Fertility support
Key reported benefits — PT-141
- ✓Increased sexual desire
- ✓CNS-mediated arousal
- ✓Works for both sexes (off-label for men)
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.